CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Netherlands' ProQR Q3 revenue rises, beats analyst estimates

By Reuters News


Overview

  • Netherlands RNA therapy developer's Q3 revenue rose and beat analyst expectations

  • Company posted Q3 net loss of €12.4 mln, or €0.09 per share

  • Quarter-end cash and equivalents at €103 mln, supporting runway into mid-2028


Outlook

  • ProQR expects initial AX-0811 Phase 1 data in early January 2027

  • Company to present full AX-0810 Phase 1 dataset and new AX-0811 preclinical data in December 2026

  • Multiple clinical milestones expected in H1 2027, including pediatric biliary atresia and MPS I Hurler syndrome trials


Result Drivers

  • CLINICAL DEVELOPMENT PROGRESS - Co attributed pipeline expansion and clinical trial advancement, especially in NTCP programs, as key operational focus areas

  • HIGHER R&D SPENDING - Increased research and development costs contributed to the quarterly net loss

  • AI AND DATA INITIATIVES - Co emphasized strengthening AI capabilities through new executive appointments and board advisory roles


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

EUR 5.16 mln

EUR 4.42 mln (6 Analysts)

Q3 Loss Per Share

EUR 0.09

Q3 Net Loss

EUR 12.45 mln

Q3 Loss Per Basic Share

EUR 0.09

Q3 Operating Income

-EUR 13.14 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for ProQR Therapeutics NV is $8.00, about 534.9% above its November 11 closing price of $1.26


Reuters Recommended Reads

  • Nov 9 - UK's Mereo BioPharma Q3 revenue beats expectations

  • Nov 10 - Germany's Immatics Q3 revenue misses estimates, net loss widens on higher spending

  • Nov 9 - Ionis Pharmaceuticals Q3 revenue rises 55%


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.